AI assistant
USCOM LIMITED — Regulatory Filings 2007
Aug 19, 2007
65979_rns_2007-08-19_7305feae-1e8a-4b6c-8f63-09944e36c4e7.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [71 x 87] intentionally omitted <==
MARKET ANNOUNCEMENT
• Third USCOM 1A to Children’s Hospital at Westmead
Monday, 20 August 2007: Uscom (ASX Code: UCM) today informed shareholders of an additional sale to The Children’s Hospital at Westmead.
This sale to the Paediatric Intensive Care Unit follows Uscom’s strategy of working closely with our installed base to develop greater demand for the product throughout the hospital. The previous Westmead sales were into the Children’s Hospital Institute of Sports Medicine (CHISM) and the Emergency Department. It is also yet another sale into our target market of paediatrics which now includes Detroit Children’s Hospital, John Hunter Hospital, Great Ormond Street, Zurich University Hospital and Sydney Children’s Hospital amongst many others.
Uscom’s CEO, Paul Butler said ‘It has always been our belief that as hospitals start to use the USCOM 1A there will be the opportunity to sell more units throughout the hospital and we are now seeing this happen at several sites.’ Paul is now based in the USA continuing the task of creating a strategic alliance and furthering the adoption of the technology.
About Uscom
Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.
The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).
USCOM CONTACTS
Paul Butler Chief Executive Officer Office: +1 646 379 3278 [email protected]
Rob Phillips Executive Chairman Office: 02 9247 4144 [email protected]
Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090
www.uscom.com.au